间充质干细胞治疗心脏疾患的研究进展  

Research progress of mesenchymal stem cells for heart diseases

作　　者：周英莲[1] 瞿海龙[1] 赵慧卿[1] 田少静[1] 扈新妹[1] 

机构地区：[1]河北大学附属医院急诊科,河北省保定市071000

出　　处：《职业与健康》2012年第15期1906-1908,共3页Occupation and Health

摘　　要：间充质干细胞(mesenchymal stem cells,MSCs)存在于多种组织内,是一种具有自我增殖和多项分化潜能的成体干细胞。MSCs体外易培养,且具有免疫调节特性,使其成为实现组织再生的种子细胞。动物心肌梗死模型证实MSCs体内移植,能够分化为心肌细胞和血管细胞,募集内源性心肌干细胞,分泌系列细胞因子,这些特性能够防止和逆转心室重构。Ⅰ期临床试验表明MSCs移植具有提高左室射血分数、抑制心室重构、减少瘢痕面积的作用。Mesenchymal stem cells（MSCs） are a kind of adult stem cell with capacity for self-renewal and differentiation,which have a broad tissue distribution.MSCs are easy to culture in vitro,and have immunoregulation function,so they are emerging as an extremely promising therapeutic agent for tissue regeneration.Studies in animal models of myocardial infarction have demonstrated the ability of transplanted MSCs to engraft and differentiate into cardiomyocytes and vasculature cells,recruit endogenous cardiac stem cells,and secrete a wide array of paracrine factors.These properties can be harnessed to both prevent and reverse remodeling in the ischemically injured ventricle.In phase I clinical trials,MSCs therapy can improve left ventricular function,induce reverse remodeling and decrease scar size.

关 键 词：间充质干细胞 再生 细胞分化 心肌梗死 

分 类 号：R542.2[医药卫生—心血管疾病]